Does the media refer more to COGT or VIR?

In the previous week, Cogent Biosciences had 1 more articles in the media than Vir Biotechnology. MarketBeat recorded 2 mentions for Cogent Biosciences and 1 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 0.67 beat Cogent Biosciences' score of 0.36 indicating that Vir Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Vir Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BLTE or VIR?

In the previous week, Belite Bio had 4 more articles in the media than Vir Biotechnology. MarketBeat recorded 5 mentions for Belite Bio and 1 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 0.67 beat Belite Bio's score of -0.54 indicating that Vir Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Vir Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VIR or APGE?

In the previous week, Apogee Therapeutics had 33 more articles in the media than Vir Biotechnology. MarketBeat recorded 34 mentions for Apogee Therapeutics and 1 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 0.67 beat Apogee Therapeutics' score of 0.61 indicating that Vir Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 12 Very Positive mention(s) 3 Positive mention(s) 14 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VIR or SRRK?

In the previous week, Scholar Rock had 4 more articles in the media than Vir Biotechnology. MarketBeat recorded 5 mentions for Scholar Rock and 1 mentions for Vir Biotechnology. Scholar Rock's average media sentiment score of 1.57 beat Vir Biotechnology's score of 0.67 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to VIR or CGON?

In the previous week, CG Oncology had 4 more articles in the media than Vir Biotechnology. MarketBeat recorded 5 mentions for CG Oncology and 1 mentions for Vir Biotechnology. CG Oncology's average media sentiment score of 1.02 beat Vir Biotechnology's score of 0.67 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vir Biotechnology (VIR) Competitors

$10.16 +0.59 (+6.17%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$10.12 -0.04 (-0.35%)

As of 06/23/2026 07:52 PM Eastern

Compare

VIR vs. COGT, BLTE, APGE, SRRK, and CGON

Should you buy Vir Biotechnology stock or one of its competitors? MarketBeat compares Vir Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vir Biotechnology include Cogent Biosciences (COGT), Belite Bio (BLTE), Apogee Therapeutics (APGE), Scholar Rock (SRRK), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry.

How does Vir Biotechnology compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Cogent Biosciences presently has a consensus price target of $43.73, indicating a potential upside of 20.43%. Vir Biotechnology has a consensus price target of $20.88, indicating a potential upside of 105.46%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Vir Biotechnology is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Cogent Biosciences has higher earnings, but lower revenue than Vir Biotechnology. Cogent Biosciences is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Vir Biotechnology	$64.69M	26.49	-$437.99M	-$3.13	N/A

Cogent Biosciences has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -53.31% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Vir Biotechnology	-638.88%	-53.31%	-41.76%

Cogent Biosciences has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market.

65.3% of Vir Biotechnology shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by company insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Cogent Biosciences had 1 more articles in the media than Vir Biotechnology. MarketBeat recorded 2 mentions for Cogent Biosciences and 1 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 0.67 beat Cogent Biosciences' score of 0.36 indicating that Vir Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vir Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vir Biotechnology beats Cogent Biosciences on 9 of the 16 factors compared between the two stocks.

How does Vir Biotechnology compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

Belite Bio has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Belite Bio's return on equity of -13.14% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
Vir Biotechnology	-638.88%	-53.31%	-41.76%

In the previous week, Belite Bio had 4 more articles in the media than Vir Biotechnology. MarketBeat recorded 5 mentions for Belite Bio and 1 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 0.67 beat Belite Bio's score of -0.54 indicating that Vir Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Vir Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Belite Bio presently has a consensus price target of $203.00, indicating a potential upside of 39.91%. Vir Biotechnology has a consensus price target of $20.88, indicating a potential upside of 105.46%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Belite Bio has higher earnings, but lower revenue than Vir Biotechnology. Belite Bio is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
Vir Biotechnology	$64.69M	26.49	-$437.99M	-$3.13	N/A

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Belite Bio has a beta of -1.24, indicating that its stock price is 224% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market.

Summary

Vir Biotechnology beats Belite Bio on 9 of the 16 factors compared between the two stocks.

How does Vir Biotechnology compare to Apogee Therapeutics?

Vir Biotechnology (NASDAQ:VIR) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Apogee Therapeutics has lower revenue, but higher earnings than Vir Biotechnology. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$64.69M	26.49	-$437.99M	-$3.13	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

Vir Biotechnology currently has a consensus target price of $20.88, indicating a potential upside of 105.46%. Apogee Therapeutics has a consensus target price of $119.67, indicating a potential downside of 9.94%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, equities analysts clearly believe Vir Biotechnology is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Apogee Therapeutics	1 Sell rating(s)	13 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.30

In the previous week, Apogee Therapeutics had 33 more articles in the media than Vir Biotechnology. MarketBeat recorded 34 mentions for Apogee Therapeutics and 1 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 0.67 beat Apogee Therapeutics' score of 0.61 indicating that Vir Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	12 Very Positive mention(s)	3 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Apogee Therapeutics has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Apogee Therapeutics' return on equity of -32.64% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-53.31%	-41.76%
Apogee Therapeutics	N/A	-32.64%	-31.25%

65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 2.9% of Vir Biotechnology shares are owned by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Vir Biotechnology has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

Summary

Vir Biotechnology beats Apogee Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Vir Biotechnology compare to Scholar Rock?

Vir Biotechnology (NASDAQ:VIR) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Scholar Rock has lower revenue, but higher earnings than Vir Biotechnology. Scholar Rock is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$64.69M	26.49	-$437.99M	-$3.13	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

In the previous week, Scholar Rock had 4 more articles in the media than Vir Biotechnology. MarketBeat recorded 5 mentions for Scholar Rock and 1 mentions for Vir Biotechnology. Scholar Rock's average media sentiment score of 1.57 beat Vir Biotechnology's score of 0.67 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Scholar Rock has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -53.31% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-53.31%	-41.76%
Scholar Rock	N/A	-163.52%	-96.67%

Vir Biotechnology currently has a consensus price target of $20.88, indicating a potential upside of 105.46%. Scholar Rock has a consensus price target of $56.00, indicating a potential upside of 9.23%. Given Vir Biotechnology's higher probable upside, research analysts plainly believe Vir Biotechnology is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 2.9% of Vir Biotechnology shares are owned by insiders. Comparatively, 13.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Vir Biotechnology has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

Summary

Scholar Rock beats Vir Biotechnology on 9 of the 16 factors compared between the two stocks.

How does Vir Biotechnology compare to CG Oncology?

Vir Biotechnology (NASDAQ:VIR) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

Vir Biotechnology has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 2.9% of Vir Biotechnology shares are owned by insiders. Comparatively, 4.8% of CG Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Vir Biotechnology presently has a consensus price target of $20.88, suggesting a potential upside of 105.46%. CG Oncology has a consensus price target of $81.73, suggesting a potential upside of 24.34%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, research analysts plainly believe Vir Biotechnology is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, CG Oncology had 4 more articles in the media than Vir Biotechnology. MarketBeat recorded 5 mentions for CG Oncology and 1 mentions for Vir Biotechnology. CG Oncology's average media sentiment score of 1.02 beat Vir Biotechnology's score of 0.67 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CG Oncology has lower revenue, but higher earnings than Vir Biotechnology. CG Oncology is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$64.69M	26.49	-$437.99M	-$3.13	N/A
CG Oncology	$5.07M	1,143.27	-$160.99M	-$2.33	N/A

CG Oncology has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. CG Oncology's return on equity of -23.33% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-53.31%	-41.76%
CG Oncology	N/A	-23.33%	-22.24%

Summary

CG Oncology beats Vir Biotechnology on 10 of the 17 factors compared between the two stocks.

Get Vir Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VIR vs. The Competition

Export

Metric	Vir Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.61B	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-3.25	19.75	24.92	23.98
Price / Sales	26.49	330.90	528.23	109.07
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	1.85	8.29	10.79	6.50
Net Income	-$437.99M	$23.85M	$3.56B	$336.88M
7 Day Performance	9.25%	2.87%	1.00%	-0.14%
1 Month Performance	10.55%	2.19%	0.42%	0.77%
1 Year Performance	92.79%	55.48%	29.70%	28.49%

Vir Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VIR Vir Biotechnology	2.129 of 5 stars	$10.16 +6.2%	$20.88 +105.5%	+101.2%	$1.61B	$64.69M	N/A	580
COGT Cogent Biosciences	2.049 of 5 stars	$33.17 +0.2%	$43.73 +31.8%	+400.1%	$5.66B	N/A	N/A	80
BLTE Belite Bio	3.0283 of 5 stars	$144.24 +4.4%	$203.00 +40.7%	+135.9%	$5.54B	N/A	N/A	10	Insider Trade
APGE Apogee Therapeutics	1.4546 of 5 stars	$86.19 -2.4%	$114.56 +32.9%	+221.4%	$5.47B	N/A	N/A	91	Trending News Analyst Downgrade Options Volume
SRRK Scholar Rock	2.1126 of 5 stars	$45.92 +3.9%	$56.00 +22.0%	+54.1%	$5.29B	N/A	N/A	140	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VIR) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vir Biotechnology (VIR) Competitors

VIR vs. COGT, BLTE, APGE, SRRK, and CGON

How does Vir Biotechnology compare to Cogent Biosciences?

Summary

How does Vir Biotechnology compare to Belite Bio?

Summary

How does Vir Biotechnology compare to Apogee Therapeutics?

Summary

How does Vir Biotechnology compare to Scholar Rock?

Summary

How does Vir Biotechnology compare to CG Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIR vs. The Competition

Vir Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vir Biotechnology (VIR) Competitors

VIR vs. COGT, BLTE, APGE, SRRK, and CGON

How does Vir Biotechnology compare to Cogent Biosciences?

Do analysts rate COGT or VIR?

Which has preferable valuation and earnings, COGT or VIR?

Is COGT or VIR more profitable?

Which has more volatility & risk, COGT or VIR?

Do institutionals and insiders believe in COGT or VIR?

Does the media refer more to COGT or VIR?

Summary

How does Vir Biotechnology compare to Belite Bio?

Is BLTE or VIR more profitable?

Does the media prefer BLTE or VIR?

Do analysts rate BLTE or VIR?

Which has higher valuation & earnings, BLTE or VIR?

Do insiders & institutionals believe in BLTE or VIR?

Which has more risk & volatility, BLTE or VIR?

Summary

How does Vir Biotechnology compare to Apogee Therapeutics?

Which has higher valuation & earnings, VIR or APGE?

Do analysts rate VIR or APGE?

Does the media prefer VIR or APGE?

Is VIR or APGE more profitable?

Do insiders & institutionals believe in VIR or APGE?

Which has more volatility & risk, VIR or APGE?

Summary

How does Vir Biotechnology compare to Scholar Rock?

Which has higher valuation and earnings, VIR or SRRK?

Does the media prefer VIR or SRRK?

Is VIR or SRRK more profitable?

Do analysts prefer VIR or SRRK?

Do institutionals & insiders believe in VIR or SRRK?

Which has more volatility & risk, VIR or SRRK?

Summary

How does Vir Biotechnology compare to CG Oncology?

Which has more risk & volatility, VIR or CGON?

Do insiders and institutionals hold more shares of VIR or CGON?

Do analysts prefer VIR or CGON?

Does the media refer more to VIR or CGON?

Which has higher earnings & valuation, VIR or CGON?

Is VIR or CGON more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIR vs. The Competition

Vir Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools